IM Cannabis director Alon Dayan resigns from board

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, reports that director Alon Dayan resigned from the board effective July 26, 2026.

Rhea-AI Filing Summary

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, reports that director Alon Dayan resigned from the board effective July 26, 2026. His resignation is described as for personal reasons and not related to any disagreement over the company’s operations, policies or practices.

The company also issued a corporate update describing its medical cannabis platform, including import, distribution and retail pharmacy activities in Israel and distribution to pharmacies in Germany, and notes that it is evaluating opportunities to expand into additional technology-driven sectors, subject to regulatory, licensing and market risks highlighted in its cautionary forward-looking statements.

Filing Explained

As a Form 6-K, this filing furnishes interim information and is incorporated by reference into four F-3 registration statements. It adds this disclosure to those registration statements, but does not itself report a new offering, sale, or issuance of shares.

Key Figures

Director resignation effective date: July 26, 2026 Corporate update press release date: July 27, 2026 Report month: July 2026

3 metrics

Director resignation effective date July 26, 2026 Date Alon Dayan’s resignation from the board became effective

Corporate update press release date July 27, 2026 Date of the IM Cannabis corporate update press release

Report month July 2026 Month covered by the Form 6-K report of foreign private issuer

Key Terms

foreign private issuer, forward-looking statements, medical cannabis

3 terms

foreign private issuer regulatory

"Report of foreign private issuer pursuant to Rule 13a-16 under the Exchange Act"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

forward-looking statements regulatory

"This press release contains forward-looking information and forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

medical cannabis medical

"a medical cannabis company with operations in Israel and Germany"

Medical cannabis is the use of cannabis plant extracts or compounds such as THC and CBD as prescribed or recommended to treat symptoms or medical conditions. Think of it as a plant-based medicine that can relieve pain, nausea, muscle spasms or other symptoms where conventional drugs may not work; for investors it matters because legal status, clinical evidence, supply rules and insurance coverage determine market size, licensing value and revenue potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did IM Cannabis Corp. (IMCC) report in July 2026?

IM Cannabis Corp. reported that director Alon Dayan resigned from its board effective July 26, 2026. The company stated his resignation was for personal reasons and not due to any disagreement over its operations, policies or practices.

Was Alon Dayan’s resignation from IM Cannabis (IMCC) related to any disagreement?

No. IM Cannabis stated that Mr. Dayan’s resignation was not related to any disagreement with the company. It specifically noted there were no issues regarding its operations, policies or practices, and characterized the change as based on personal reasons.

What markets does IM Cannabis Corp. (IMCC) currently serve?

IM Cannabis operates a medical cannabis platform in Israel and Germany. In Israel it imports, distributes and sells through pharmacies and online platforms, while in Germany its subsidiary Adjupharm GmbH distributes medical cannabis to pharmacies serving patients.

What future opportunities is IM Cannabis (IMCC) evaluating?

The company states it is evaluating opportunities to expand into additional technology-driven sectors. Any such expansion depends on its ability to identify suitable opportunities, maintain required licences and permits, and operate under evolving market and regulatory conditions.

What key risks does IM Cannabis Corp. (IMCC) highlight in its forward-looking statements?

IM Cannabis highlights risks tied to the highly regulated medical cannabis industry, maintaining licences and approvals, legal and regulatory changes, market conditions in Israel and Germany, availability of strategic opportunities, and the company’s liquidity and capital resources.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 05:00 PM Accepted by SEC EDGAR 07/27/2026 - 05:00 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026 (Report No. 2).

Commission File Number: 001-40065

 
IM Cannabis Corp.
(Exact Name of Registrant as Specified in Charter)

Kibbutz Glil Yam, Central District, Israel 4690500
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Resignation of a Director

On July 26, 2026, Mr. Alon Dayan notified the board of directors of IM Cannabis Corp. (the “Company”) of his resignation from his position as a member of the board of directors, effective July 26, 2026. Mr. Dayan’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

Press Release

On July 27, 2026, the Company issued a press release titled: “IM Cannabis Provides Corporate Update”. A copy of this press release is furnished herewith as Exhibit 99.1.

Incorporation by Reference

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-296637, 333-293236, 333-289571 and 333-288346) filed with the U.S. Securities and Exchange Commission to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1	Press Release dated July 27, 2026, titled “IM Cannabis Provides Corporate Update”.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IM CANNABIS CORP.
	(Registrant)
Date: July 27, 2026	By:	/s/ Oren Shuster
	Name:	Oren Shuster
	Title:	Chief Executive Officer and Director

Exhibit 99.1

IM Cannabis Provides Corporate Update

TORONTO and GLIL YAM, Israel, July 27, 2026 – IM Cannabis Corp. (“IMC” or the “Company”) (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, announces that Mr. Alon Dayan has resigned as a director of the Company for personal reasons.

The board of directors and management of IM Cannabis thank Mr. Dayan for his service and valuable contributions to the Company during his tenure and extend their best wishes to him in his future endeavours.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.

The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Company Contact:

Michal Efraty

Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com

Oren Shuster, Chief Executive Officer

IM Cannabis Corp.

info@imcannabis.com

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws and, where applicable, United States securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s evaluation of opportunities to expand into additional technology-driven sectors and the Company’s business focus, strategy and future opportunities.

Forward-looking statements are based on the beliefs, expectations and assumptions of management as of the date of this press release, including assumptions regarding the Company’s ability to continue operating its medical cannabis platform in Israel and Germany, the availability of opportunities that are consistent with the Company’s business strategy, the Company’s ability to evaluate and pursue such opportunities, market conditions, regulatory conditions and the continued availability of required licences, permits and approvals.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, risks relating to the highly regulated nature of the medical cannabis industry, the Company’s ability to maintain applicable licences, permits and regulatory approvals, changes in applicable laws, regulations and enforcement practices, market and business conditions in Israel and Germany, the availability and suitability of strategic opportunities, the Company’s liquidity and capital resources, and the risks described under the heading “Risk Factors” in the Company’s most recent annual report and other continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.1 KB